

While some quibble with the details, there's a consensus that America's infrastructure is in massive need of repair and that this kind of investment would be a boost to the economy. Her infrastructure plan has been widely praised by economists across the political spectrum. "When your paycheck grows, America grows." "The heart of my plan will be the biggest investment in American infrastructure in decades," she said. All Rights Reserved.Related: Hillary Clinton's best economic idea All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates.

Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. Factset: FactSet Research Systems Inc.2019.

Market indices are shown in real time, except for the DJIA, which is delayed by two minutes.

Still, investors are clearly worried Shkreli used some of the same strategies that have gotten the attention of Clinton. Retrophin was founded by Shkreli, but he was fired by Retrophin last year and the company has since sued him. One of the hardest-hit biotech stocks was Retrophin ( RTRX), which plummeted 14% on Monday. The industry has benefited from huge demand for next-generation drugs and a wave of mergers & acquisitions. The iShares biotech ETF has skyrocketed nearly 300% over the past five years, vastly outperforming the broader markets. Related: The Silicon Valley recipe to win 2016 electionīiotech stocks have been on fire for years. Other big biotech names under pressure include Regeneron Pharmaceuticals ( REGN), Gilead Sciences ( GILD) and Celgene ( CELG). The nine biggest losers on the Nasdaq 100 were all biotech stocks, led by BioMarin Pharmaceutical ( BMRN) and Biogen ( BIIB), both of which tumbled 6% apiece. The iShares Nasdaq Biotechnology ETF ( IBB) went from flat on the day before the Clinton tweet to closing down nearly 5%.īiotech stocks helped knock the Nasdaq into the red on what had been an otherwise positive day for U.S. The former first lady's comments clearly spooked investors. "We are committed to ensuring easy and affordable access to this important treatment," Turing said in a statement. That includes offering the treatment without charge to qualified, uninsured patients and a co-pay assistance program for insured patients. The drug company said it has established a number of financial assistance programs for Daraprim. Shkreli defended the price increase to the Times, saying: "This isn't the greedy drug company trying to gouge patients, it is us trying to stay in business." The drug highlighted by the Times was acquired in August by Turing Pharmaceuticals, a privately held startup that's run by former hedge fund manager Martin Shkreli. Related: Why Clinton's profit-sharing proposal may not do much
